This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stewart, R. J. Articles by Stevens, M. C.G. Search for Related Content PubMed PubMed Citation Articles by Stewart, R. J. Articles by Stevens, M. C.G. Social Bookmarking                            What's this?

Treatment of Children With Nonmetastatic Paratesticular Rhabdomyosarcoma: Results of the Malignant Mesenchymal Tumors Studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology

From the Queen’s Medical Centre, Nottingham, and Royal Hospital for Children, Bristol, United Kingdom; Bicêtre Hospital, Le Kremlin-Bicêtre, and Institut Gustave Roussy, Villejuif, France; and Marciniak Hospital, Wroclaw, Poland.

Address reprint requests to Hélène Martelli, MD, PhD, Department of Paediatric Surgery, Bicêtre Hospital, 78, rue du Général Leclerc, 94275 Le Kremlin, Bicêtre Cedex, France; email: helene.martelli{at}bct.ap-hop-paris.fr.

Purpose: To report the results of the Malignant Mesenchymal Tumors studies (MMT 84 and 89) of the International Society of Pediatric Oncology (SIOP) in males with nonmetastatic paratesticular rhabdomyosarcoma.

Patients and Methods: From 1984 to 1994, 96 males were treated in SIOP protocols. Radical inguinal orchidectomy was recommended, but initial retroperitoneal lymph node dissection was not performed. Disease was staged according to the SIOP tumor-node-metastasis staging system. Treatment was stratified by stage. In the MMT 89 study, males with completely resected tumors at diagnosis received less chemotherapy (vincristine and dactinomycin) than patients in the MMT 84 study (ifosfamide, vincristine, and dactinomycin).

Results: Median age at diagnosis was 65 months. Thirty-one tumors were larger than 5 cm, and 13 males were older than 10 years with a tumor larger than 5 cm. At a median follow-up of 7 years, 87 patients were alive; 79 were in first complete remission and eight were in second complete remission. Relapse occurred in 16 patients (17%). At 5 years, the overall survival (OS) rate was 92%, with an event-free survival (EFS) rate of 82%. OS and EFS were significantly worse for males with tumors greater than 5 cm and for males older than 10 years at diagnosis.

Conclusion: Males with paratesticular RMS have an excellent prognosis except for a selected group of patients older than 10 years or with tumor greater than 5 cm. Intensified chemotherapy incorporating alkylating agents for this subgroup may be preferred to the use of systematic lymphadenectomy to improve survival while minimizing the burden of therapy.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. C.G. Stevens, A. Rey, N. Bouvet, C. Ellershaw, F. Flamant, J. L. Habrand, H. B. Marsden, H. Martelli, J. S. de Toledo, R. D Spicer, et al. Treatment of Nonmetastatic Rhabdomyosarcoma in Childhood and Adolescence: Third Study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89 J. Clin. Oncol., April 20, 2005; 23(12): 2618 - 2628. [Abstract] [Full Text] [PDF]